Satellos Bioscience Inc.

Satellos Bioscience announced positive six-month interim data from its TRAILHEAD study for SAT-3247 in adults with Duchenne muscular dystrophy (DMD). The investigational drug showed reduced muscle fat fraction, increased total effort, stable strength, and lower creatine kinase (CK) levels. The safety profile remained favorable and consistent with previous reports, with all four participants showing improvements in key metrics despite the advanced stage of their disease. The company plans to complete enrollment in the BASECAMP study and initiate US clinical trial sites for TRAILHEAD in Q3.

Satellos Bioscience Inc. announced positive six-month interim data from its TRAILHEAD study for investigational drug SAT-3247 in adults with Duchenne muscular dystrophy. The results showed reduced muscle fat fraction, increased total upper limb effort, stable strength, and lower muscle damage biomarkers. The drug maintained a favorable safety profile, and the company plans to complete enrollment in its BASECAMP study and initiate US clinical trial sites for TRAILHEAD in the third quarter.

Satellos Bioscience announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne Muscular Dystrophy (DMD). This designation, along with prior Orphan Drug and Rare Pediatric Disease designations, aims to expedite the development and review of the drug. The company is currently advancing SAT-3247 through its Phase 2 BASECAMP and TRAILHEAD studies, with additional data anticipated in the second half of 2026.

Satellos Bioscience Inc. announced it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy, from July 7–11, 2026. The presentations will include a poster detailing six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD (LT-001) trial. Wildon Farwell, MD, MPH, Satellos' Chief Medical Officer, will present both the poster and a Showcase Theatre presentation on advancing muscle repair with SAT-3247, an investigational oral small molecule for degenerative muscle diseases like Duchenne muscular dystrophy.

Satellos Bioscience Inc. announced it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy, from July 7-11, 2026. The presentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b SAT-3247-CL-101 trial and enrolled in the ongoing Phase 2 TRAILHEAD study. Additionally, the company's Chief Medical Officer will deliver a Showcase Theatre presentation on advancing muscle repair with SAT-3247, an investigational oral drug for Duchenne muscular dystrophy and other degenerative muscle diseases.

Satellos Bioscience Inc. held its annual meeting of shareholders virtually on June 17, 2026. Shareholders elected all nine director nominees to hold office until the next annual meeting. Additionally, PricewaterhouseCoopers LLP was appointed as the company's auditor, with directors authorized to fix its remuneration. Approximately 55.33% of the company's issued and outstanding shares were represented at the meeting.

Satellos Bioscience Inc. announced the results of its Annual Meeting of Shareholders held on June 17, 2026. All nominees listed in the management information circular were successfully elected as directors, with shareholder participation at 55.3% of issued and outstanding common shares. Additionally, shareholders voted in favor of re-appointing PricewaterhouseCoopers LLP as the company's auditors.

Satellos Bioscience Inc. announced its participation in two investor conferences in June 2026. The company will present at the Jefferies Global Healthcare Conference on June 4 and join a panel at the Oppenheimer CNS & Neuro-Muscular Summit on June 10. Members of the leadership team will also be available for one-on-one investor meetings, and the presentation will be webcast live with a replay available afterward. Satellos is a clinical-stage drug development company focused on SAT-3247 for degenerative muscle diseases like DMD.

Satellos Bioscience Inc. announced that its management team will participate in two investor conferences in June. The company will attend the Jefferies Global Healthcare Conference on June 4, 2026, delivering a presentation. Additionally, Satellos will participate in the Oppenheimer CNS & Neuro-Muscular Summit on June 10, joining a panel discussion. Webcasts of the presentations will be available, and management will hold one-on-one investor meetings.

Satellos Bioscience Inc. announced its Annual General Meeting (AGM) of shareholders will be held virtually on June 17, 2026, at 1:00 p.m. Toronto time. Shareholders will vote on the election of nine directors, the appointment of PricewaterhouseCoopers LLP as auditors, and receive the audited financial statements for the year ended December 31, 2025. The Board recommends voting in favor of all resolutions, and the record date for voting is May 12, 2026.